Table 5 Responsiveness of the SF-36v2 scales and summary scores (N = 387)
| Â | Â | Â | Â | SRM (95% CI) | ||
|---|---|---|---|---|---|---|
Scales | Baseline | 6-month change | P | Total sample | Low disease activity | Moderate-high |
(DAS28 ≤3.2) | disease activity | |||||
Mean (SD) | Mean (SD) | |||||
(n = 232) | (n = 101) | |||||
PF | 57.05 (25.30) | 10.10 (21.47) | <0.001 | 0.47 (0.37 to 0.58) | 0.72 (0.58 to 0.85) | 0.19 (0.00 to 0.38) |
RP | 45.45 (27.41) | 12.90 (27.01) | <0.001 | 0.47 (0.36 to 0.58) | 0.66 (0.53 to 0.79) | 0.20 (0.01 to 0.38) |
BP | 45.16 (21.10) | 18.20 ( 24.61) | <0.001 | 0.76 (0.65 to 0.85) | 1.07 (0.94 to 1.19) | 0.40 (0.22 to 0.58) |
GH | 55.60 (18.30) | 2.76 (16.41) | 0.001 | 0.17 (0.05 to 0.27) | 0.40 (0.27 to 0.52) | −0.21 (0.41 to −0.00) |
VT | 53.60 (20.61) | 5.56 ( 17.72) | <0.001 | 0.31 (0.21 to 0.42) | 0.53 (0.39 to 0.66) | 0.02 (−0.17 to 0.22) |
SF | 70.99 (24.43) | 8.04 ( 24.08) | <0.001 | 0.33 (0.22 to 0.44) | 0.52 (0.39 to 0.65) | 0.11 (−0.11 to 0.33) |
RE | 66.88 (28.35) | 3.47 (26.79) | 0.011 | 0.13 (0.03 to 0.23) | 0.31 (0.18 to 0.44) | −0.19 (−0.40 to 0.02) |
MH | 71.62 (19.22) | 3.88 (17.68) | <0.001 | 0.22 (0.12 to 0.33) | 0.37 (0.23 to 0.50) | 0.05 (−0.16 to 0.27) |
PCS | 37.13 (9.18) | 5.62 (8.58) | <0.001 | 0.66 (0.55 to 0.76) | 0.93 (0.80 to 1.07) | 0.32 (0.14 to 0.50) |
MCS | 48.33 (11.64) | 0.98 (9.95) | 0.052 | 0.10 (0.00 to 0.21) | 0.26 (0.12 to 0.39) | −0.15 (−0.36 to 0.07) |